Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice

Takayoshi Mamiya, Yukihiro Noda, Akihiro Noda, Masayuki Hiramatsu, Katsuhiro Karasawa, Tsutomu Kameyama, Shoei Furukawa, Kiyofumi Yamada, Toshitaka Nabeshima

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In this study, we investigated the involvement of the interaction between sigma receptors and the nitric oxide/cyclic GMP pathway in short term memory in mice, assessed through spontaneous alternation behavior in a Y-maze. N(G)-Nitro-L-arginine methyl ester and 7-nitro indazole, both nitric oxide synthase inhibitors, impaired the spontaneous alternation behavior. These impairments were attenuated by (+) SKF 10,047 and (+) pentazocine, sigma1 receptor agonists. Further, the sigma1 receptor antagonist, NE-100, reversed the improvements made by sigma receptor agonists. Cyclic GMP levels and nitric oxide synthase activity in the hippocampus were reduced by treatment with N(G)-nitro-L-arginine methyl ester. The suppressive effects of N(G)-nitro-L-arginine methyl ester on the cyclic GMP levels were reversed by co-treatment with (+) SKF 10,047, but the decline in nitric oxide synthase activity was not. These results suggest that the nitric oxide/cyclic GMP pathway in the hippocampus is responsible for spontaneous alternation behavior in a Y-maze. Further, the ameliorating effects of (+) SKF 10,047 on the impairment of spontaneous alternation behavior may be mediated through activation of guanylate cyclase, but not nitric oxide synthase in the hippocampus of mice. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)2391-2398
Number of pages8
JournalNeuropharmacology
Volume39
Issue number12
DOIs
Publication statusPublished - 01-11-2000

Fingerprint

sigma Receptors
Cyclic GMP
Nitric Oxide Synthase
NG-Nitroarginine Methyl Ester
Hippocampus
Nitric Oxide
Pentazocine
Guanylate Cyclase
Short-Term Memory

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Mamiya, Takayoshi ; Noda, Yukihiro ; Noda, Akihiro ; Hiramatsu, Masayuki ; Karasawa, Katsuhiro ; Kameyama, Tsutomu ; Furukawa, Shoei ; Yamada, Kiyofumi ; Nabeshima, Toshitaka. / Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice. In: Neuropharmacology. 2000 ; Vol. 39, No. 12. pp. 2391-2398.
@article{37e72732eedf41b2813700abc0b8a1b9,
title = "Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice",
abstract = "In this study, we investigated the involvement of the interaction between sigma receptors and the nitric oxide/cyclic GMP pathway in short term memory in mice, assessed through spontaneous alternation behavior in a Y-maze. N(G)-Nitro-L-arginine methyl ester and 7-nitro indazole, both nitric oxide synthase inhibitors, impaired the spontaneous alternation behavior. These impairments were attenuated by (+) SKF 10,047 and (+) pentazocine, sigma1 receptor agonists. Further, the sigma1 receptor antagonist, NE-100, reversed the improvements made by sigma receptor agonists. Cyclic GMP levels and nitric oxide synthase activity in the hippocampus were reduced by treatment with N(G)-nitro-L-arginine methyl ester. The suppressive effects of N(G)-nitro-L-arginine methyl ester on the cyclic GMP levels were reversed by co-treatment with (+) SKF 10,047, but the decline in nitric oxide synthase activity was not. These results suggest that the nitric oxide/cyclic GMP pathway in the hippocampus is responsible for spontaneous alternation behavior in a Y-maze. Further, the ameliorating effects of (+) SKF 10,047 on the impairment of spontaneous alternation behavior may be mediated through activation of guanylate cyclase, but not nitric oxide synthase in the hippocampus of mice. Copyright (C) 2000 Elsevier Science Ltd.",
author = "Takayoshi Mamiya and Yukihiro Noda and Akihiro Noda and Masayuki Hiramatsu and Katsuhiro Karasawa and Tsutomu Kameyama and Shoei Furukawa and Kiyofumi Yamada and Toshitaka Nabeshima",
year = "2000",
month = "11",
day = "1",
doi = "10.1016/S0028-3908(00)00078-2",
language = "English",
volume = "39",
pages = "2391--2398",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "12",

}

Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice. / Mamiya, Takayoshi; Noda, Yukihiro; Noda, Akihiro; Hiramatsu, Masayuki; Karasawa, Katsuhiro; Kameyama, Tsutomu; Furukawa, Shoei; Yamada, Kiyofumi; Nabeshima, Toshitaka.

In: Neuropharmacology, Vol. 39, No. 12, 01.11.2000, p. 2391-2398.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice

AU - Mamiya, Takayoshi

AU - Noda, Yukihiro

AU - Noda, Akihiro

AU - Hiramatsu, Masayuki

AU - Karasawa, Katsuhiro

AU - Kameyama, Tsutomu

AU - Furukawa, Shoei

AU - Yamada, Kiyofumi

AU - Nabeshima, Toshitaka

PY - 2000/11/1

Y1 - 2000/11/1

N2 - In this study, we investigated the involvement of the interaction between sigma receptors and the nitric oxide/cyclic GMP pathway in short term memory in mice, assessed through spontaneous alternation behavior in a Y-maze. N(G)-Nitro-L-arginine methyl ester and 7-nitro indazole, both nitric oxide synthase inhibitors, impaired the spontaneous alternation behavior. These impairments were attenuated by (+) SKF 10,047 and (+) pentazocine, sigma1 receptor agonists. Further, the sigma1 receptor antagonist, NE-100, reversed the improvements made by sigma receptor agonists. Cyclic GMP levels and nitric oxide synthase activity in the hippocampus were reduced by treatment with N(G)-nitro-L-arginine methyl ester. The suppressive effects of N(G)-nitro-L-arginine methyl ester on the cyclic GMP levels were reversed by co-treatment with (+) SKF 10,047, but the decline in nitric oxide synthase activity was not. These results suggest that the nitric oxide/cyclic GMP pathway in the hippocampus is responsible for spontaneous alternation behavior in a Y-maze. Further, the ameliorating effects of (+) SKF 10,047 on the impairment of spontaneous alternation behavior may be mediated through activation of guanylate cyclase, but not nitric oxide synthase in the hippocampus of mice. Copyright (C) 2000 Elsevier Science Ltd.

AB - In this study, we investigated the involvement of the interaction between sigma receptors and the nitric oxide/cyclic GMP pathway in short term memory in mice, assessed through spontaneous alternation behavior in a Y-maze. N(G)-Nitro-L-arginine methyl ester and 7-nitro indazole, both nitric oxide synthase inhibitors, impaired the spontaneous alternation behavior. These impairments were attenuated by (+) SKF 10,047 and (+) pentazocine, sigma1 receptor agonists. Further, the sigma1 receptor antagonist, NE-100, reversed the improvements made by sigma receptor agonists. Cyclic GMP levels and nitric oxide synthase activity in the hippocampus were reduced by treatment with N(G)-nitro-L-arginine methyl ester. The suppressive effects of N(G)-nitro-L-arginine methyl ester on the cyclic GMP levels were reversed by co-treatment with (+) SKF 10,047, but the decline in nitric oxide synthase activity was not. These results suggest that the nitric oxide/cyclic GMP pathway in the hippocampus is responsible for spontaneous alternation behavior in a Y-maze. Further, the ameliorating effects of (+) SKF 10,047 on the impairment of spontaneous alternation behavior may be mediated through activation of guanylate cyclase, but not nitric oxide synthase in the hippocampus of mice. Copyright (C) 2000 Elsevier Science Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0033884099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033884099&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(00)00078-2

DO - 10.1016/S0028-3908(00)00078-2

M3 - Article

C2 - 10974323

AN - SCOPUS:0033884099

VL - 39

SP - 2391

EP - 2398

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 12

ER -